OLFADOG BIOTECH
The computed 12-month bankruptcy probability of OLFADOG BIOTECH is 1.0% (low). The 2024 annual accounts show equity of €1.44M and a net result of €-189k. Its solvency ranks better than 87% of 42 sector peers (fiscal year 2024). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €1.44M |
| Net result | €-189k |
| Better than sector | 87% |
| Active | 3 yrs |
Mixed profile: strong on solvency, weaker on profitability.
Computed on 4 of 5 axes. Not measured: growth. An unmeasured axis is not a zero: no data was read for it.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 80.0% | 53.6% | |
| Net result | €-189k | €-16k | |
| Equity | €1.44M | €644k | |
| Gross operating margin | €-8k | €7k | |
| Total assets | €1.80M | €1.71M |
| Fiscal year | 2024 |
|---|---|
| Deposit | volledig |
| Revenue | - |
| EBITDA | €-9k |
| Net profit | €-189k |
| Cash flow | €-9k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €1.80M |
| Equity | €1.44M |
| Debt | €360k |
| of which ≤ 1y | €360k |
| of which > 1y | - |
| Working capital | €482k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 2.34 |
| Quick ratio | 2.34 |
| Working capital ratio | 26.8% |
| Solvency | 80.0% |
| Debt / equity | 0.25 |
| Long-term debt ratio | - |
| Interest coverage | -55.53 |
| Gross margin | - |
| Net margin | - |
| ROA | -10.5% |
| ROE | -13.1% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €1.80M |
| Fixed assets | 21/28 | €960k |
| Intangible fixed assets | 21 | €960k |
| Current assets | 29/58 | €843k |
| Amounts receivable within one year | 40/41 | €2k |
| Cash & bank | 54/58 | €634k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €1.80M |
| Equity | 10/15 | €1.44M |
| Contributions / capital | 10/11 | €2.04M |
| Accumulated profits (losses) | 14 | €-593k |
| Amounts payable | 17/49 | €360k |
| Amounts payable within one year | 42/48 | €360k |
| Trade debts payable within one year | 44 | €360k |
| Income statement | ||
| Gross operating margin | 9900 | €-8k |
| Operating result | 9901 | €-189k |
| Financial charges | 65 | €155 |
| Result before taxes | 9903 | €-189k |
| Net result for the period | 9904 | €-189k |
| Result to be appropriated | 9905 | €-189k |
| NACE primary | Speur- en ontwikkelingswerk op biotechnologisch gebied(72101) |
| Legal form | Public limited company(014) |
| Incorporation | 16-12-2022 |
| Status | Active |
| Postal code | 1410 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25763M0600/00V000 | Wallonia | 1.3 ha | 1 · 895 m² | 14.8 m · 4 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
06-01-2025 Capital increase of €786,417 to €2,035,417
- €1.249.000 → €2.035.417
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 2035417.0,
"delta_eur": 786417.0,
"before_eur": 1249000.0,
"share_emission": {
"agio_eur": 0.0,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": 786417,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 1.0
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 786417.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Dominique ROULEZ",
"firm_city": null,
"firm_name": null,
"office_city": "Waterloo",
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-01-06",
"filing_date": "2025-01-02",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2024-12-12",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": {
"waived": true,
"firm_kbo": null,
"firm_name": null,
"ibr_number": null,
"mission_type": null,
"individual_name": null
},
"subject_company": {
"kbo": "0794.892.333",
"name_full": "OLFADOG BIOTECH",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"texte coordonn\u00E9 des statuts",
"procurations"
],
"shareholders_after": [],
"share_classes_after": []
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | OLFADOG BIOTECH |
| AbbreviationFR | OLFADOG |